European journal of pharmacology · 2026
Targeting lipid metabolism-associated lncHMGCS1 suppressed cell proliferation and restored intracellular lipid homeostasis by regulating ACSL3 in gastric cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Qiang, He Yuyang, Wang Lejia, Yuan Xiaoxia, Zhang Jingping, Chen Jinxin, Jiang Guohui, Ma Wenrong, Lu Xingtong, Wei Chen, Zhang Bin, Deng Shihao, Luo Yaomin, Xiao Yang, Long Kexun, Xu Chaoying, Yin Xinqiang, Jiang Zhen
Аннотация
Previous work has indicated that lipid metabolic reprogramming plays a critical role in gastric cancer (GC) development, yet the underlying molecular mechanisms remain largely undefined. In the present study, we identified a novel lipid metabolism-associated long non-coding RNA, 3-Hydroxy-3-Methylglutaryl-CoA Synthase 1 (lncHMGCS1), which is aberrantly upregulated in GC tissues and cell lines. Functional assays demonstrated that lncHMGCS1 overexpression could promote intracellular lipid droplet accumulation, elevate the triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, and enhance GC cell proliferation. Mechanistically, lncHMGCS1 can suppress expression of miR-18b-5p, a microRNA that directly targets both lncHMGCS1 and acyl-CoA synthetase long-chain family member 3 (ACSL3). ACSL3 knockdown reversed the oncogenic effects of lncHMGCS1 on GC cells in a miR-18b-5p-dependent manner, highlighting the critical role of the lncHMGCS1-ACSL3 axis in lipid metabolic reprogramming. Collectively, our findings establish lncHMGCS1 as a driver of lipid metabolism and tumorigenesis in GC, laying the groundwork for the development of novel diagnostic and therapeutic targets for managing this disease.